FDA Approves Lisraya (Brepocitinib) for Adults With Dermatomyositis

The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) 30 mg for the treatment of adults living with dermatomyositis, a rare autoimmune disease that can affect the muscles, skin, and everyday physical functioning.

The approval, announced by Roivant on August 27, 2026, represents a significant development in the treatment landscape for dermatomyositis. Lisraya is designed as a once-daily oral medicine and is described by Roivant as the first targeted therapy specifically approved for adults with the condition.

Dermatomyositis can be a challenging disease to manage because it may cause progressive muscle weakness alongside painful, itchy, and sometimes extensive skin problems. These symptoms can interfere with basic activities, physical independence, comfort, and quality of life. Many patients have traditionally relied on corticosteroids and other immune-modulating treatments to control their disease.

What Is Dermatomyositis?

Dermatomyositis is a systemic autoimmune disorder in which the body's immune system mistakenly attacks healthy tissues. The condition is commonly associated with muscle inflammation and distinctive skin changes.

People with dermatomyositis can experience weakness that makes everyday activities difficult. Tasks such as climbing stairs, getting dressed, carrying objects, or completing household errands may become more challenging. Skin symptoms can include rashes, sensitivity, itching, and discomfort.

Treatment is often focused on controlling inflammation and reducing disease activity. Corticosteroids may play an important role, although long-term steroid treatment can bring its own risks and side effects. This has created interest in therapies that can control the underlying immune activity while potentially reducing dependence on steroids.

How Lisraya Works

Lisraya contains brepocitinib, a small-molecule medicine that targets two immune signaling pathways, JAK1 and TYK2.

These pathways are involved in immune system signaling and have been linked to inflammatory and autoimmune processes. By inhibiting these pathways, brepocitinib is intended to reduce abnormal immune activity associated with dermatomyositis.

According to Roivant, Lisraya is the first targeted therapy approved for dermatomyositis and can be prescribed to adults with the condition regardless of their level of disease activity, clinical presentation, or previous treatment experience.

The company also states that the medicine may be used either as an alternative treatment or alongside certain existing non-targeted therapies, depending on an individual patient's circumstances.

Evidence From the VALOR Clinical Trial

The FDA's decision follows results from the Phase 3 VALOR study, which Roivant describes as the largest clinical trial conducted in dermatomyositis.

The study evaluated disease improvement using the Myositis Total Improvement Score, a composite measure that considers several aspects of disease activity. According to the company, improvements were observed as early as the fourth week of treatment and continued through the 52-week study period.

One particularly important finding involved corticosteroid use.

Among participants receiving Lisraya, 55% achieved moderate or greater improvement on the Total Improvement Score while also reaching minimal or no steroid use by the end of the study. This compared with 30% of participants receiving placebo.

The trial also examined patients who were taking at least 7.5 mg per day of prednisone-equivalent corticosteroids at the beginning of the study. By week 52, 62% of those receiving Lisraya had reduced their steroid use to 2.5 mg per day or less, compared with 38% of participants receiving placebo.

In addition, 45% of patients in this Lisraya group were able to stop corticosteroids completely, compared with 29% in the placebo group.

Steroid reduction can be an important treatment goal because prolonged corticosteroid exposure can be associated with significant complications. However, decisions about reducing or stopping steroids must be made by a healthcare professional and should not be based on clinical trial percentages alone.

Benefits Reported Across Skin and Muscle Symptoms

The reported benefits of Lisraya were not limited to a single measure of disease activity.

According to Roivant, participants receiving the medicine also showed improvements in measures related to skin disease and muscle strength. The trial additionally assessed outcomes that reflected patients' own experiences with dermatomyositis.

Patients were asked to assess the overall activity of their disease. Roivant reported that people receiving Lisraya experienced more than four times the improvement reported by those receiving placebo on this measure.

The study also looked at everyday physical functioning. This included activities such as dressing, climbing stairs, and running errands. The company reported clinically meaningful improvements among participants receiving Lisraya, while the placebo group experienced worsening on this measure.

These findings are potentially important because treating dermatomyositis involves more than improving laboratory measurements or clinical scores. For patients, successful treatment can also mean being able to move more easily, perform daily tasks, and maintain greater independence.

Safety Remains an Important Consideration

Although the approval provides a new treatment option, Lisraya is not without safety considerations.

The prescribing information contains a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Because brepocitinib affects immune signaling, patients may have an increased risk of serious infections.

The prescribing information highlights risks including tuberculosis, invasive fungal infections, herpes zoster, and other bacterial or viral infections. Patients should be evaluated for tuberculosis before and during treatment as appropriate.

Other warnings include potential cardiovascular events, blood clots, certain cancers, gastrointestinal perforation, changes in blood counts and liver enzymes, and hypoglycemia in some patients with diabetes.

The medicine is also contraindicated in people with known hypersensitivity to brepocitinib or its ingredients. It is not recommended for people with severe hepatic or severe renal impairment, according to the supplied prescribing information.

The most commonly reported adverse reactions in the VALOR trial included upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, bronchitis, joint pain, diarrhea, back pain, falls, influenza, and acne.

Patients and healthcare professionals should review the complete prescribing information before starting treatment.

What the Approval Could Mean for Patients

The approval of Lisraya gives adults with dermatomyositis another treatment option at a time when researchers and clinicians are looking for more targeted approaches to autoimmune disease.

Its once-daily oral format may also offer a practical alternative for some patients compared with therapies that require injections or intravenous administration. However, whether Lisraya is appropriate will depend on an individual's medical history, other medications, disease characteristics, and potential risk factors.

Access is another consideration. Roivant has stated that Lisraya will initially be available through a limited distribution network of specialty pharmacies. The company also says that its patient support program can provide assistance related to insurance coverage and financial support for eligible patients.

The approval follows earlier regulatory recognition, including Priority Review and Orphan Drug Designation.

A New Chapter in Dermatomyositis Treatment

The FDA approval of Lisraya marks an important development for adults with dermatomyositis. Clinical trial results indicate that the medicine can improve several measures of disease activity while also helping some patients reduce their reliance on corticosteroids.

At the same time, the treatment carries significant warnings that patients need to understand. The approval does not mean Lisraya is appropriate for everyone with dermatomyositis, and treatment decisions should be made with a qualified healthcare professional.

As longer-term experience with brepocitinib develops, physicians and researchers will have more information about its effectiveness, safety, and role alongside existing treatments. For now, its approval provides a new targeted option for adults living with a disease that can substantially affect both physical health and daily life.

Source

Roivant, including information concerning the FDA approval, the Phase 3 VALOR trial, reported efficacy results, adverse reactions, and prescribing information.

Disclaimer

This article is for general informational and educational purposes only. It is not medical advice, a diagnosis, or a recommendation to start, stop, or change any medication. FDA approval and clinical trial results do not guarantee that a medicine will be appropriate or effective for every individual. Lisraya carries important safety warnings, including risks of serious infections, malignancy, cardiovascular events, and thrombosis. Anyone considering treatment for dermatomyositis should discuss the potential benefits, risks, contraindications, and alternatives with a qualified healthcare professional and consult the medicine's official prescribing information.